Stock MIRM MIRUM PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Mirum Pharmaceuticals, Inc.

Equities

MIRM

US6047491013

Real-time Estimate Cboe BZX
Other stock markets
 11:10:03 2024-04-26 am EDT 		5-day change 1st Jan Change
24.6 USD +0.43% Intraday chart for Mirum Pharmaceuticals, Inc. +3.02% -16.90%
Apr. 17 Stifel Initiates Mirum Pharmaceuticals With Buy Rating, $48 Price Target MT
Apr. 02 Mirum Pharmaceuticals, Inc. receives Positive Reimbursement Recommendation for Livmarli (Maralixibat Oral Solution) by Canada?S Cadth for Patients with Cholestatic Pruritus in Alagille Syndrome CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Stifel Initiates Mirum Pharmaceuticals With Buy Rating, $48 Price Target
MT
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
Mirum Pharmaceuticals LIVMARLI Receives Positive Reimbursement Recommendation by Canada s CADTH for Patients with Cholestatic Pruritusin Alagille Syndrome
AQ
Mirum Pharmaceuticals’ LIVMARLI (maralixibat oral solution) Receives Positive Reimbursement Recommendation by Canada’s CADTH for Patients with Cholestatic Pruritus in Alagille Syndrome
BU
Mirum Pharmaceuticals, Inc. receives Positive Reimbursement Recommendation for Livmarli (Maralixibat Oral Solution) by Canada?S Cadth for Patients with Cholestatic Pruritus in Alagille Syndrome
CI
JMP Securities Raises Price Target on Mirum Pharmaceuticals to $72 From $69, Maintains Market Outperform Rating
MT
Sector Update: Health Care Stocks Mixed Pre-Bell Thursday
MT
Sector Update: Health Care
MT
HC Wainwright Adjusts Mirum Pharmaceuticals Price Target to $58 From $45, Maintain Buy Rating
MT
Mirum Pharmaceuticals Says FDA Approved Familial Intrahepatic Cholestasis Treatment
MT
Mirum Pharmaceuticals Gets Additional FDA Approval for Livmarli
DJ
US FDA approves expanded use of Mirum's liver disease drug
RE
Mirum Pharmaceuticals’ LIVMARLI Receives FDA Approval for Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis
BU
Mirum Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Approve LIVMARLI (Maralixibat) Oral Solution for the Treatment of Cholestatic Pruritus in Patients Five Years of Age and Older with Progressive Familial Intrahepatic Cholestasis
CI
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
BU
Cantor Fitzgerald Adjusts Price Target on Mirum Pharmaceuticals to $40 From $35, Maintains Overweight Rating
MT
Mirum Pharmaceuticals - Hepatology Publishes Six-Year Data Demonstrating Improved Clinical Outcomes in Patients with Alagille Syndrome Treated with Mirum's LIVMARLI
AQ
Hepatology Publishes Six-Year Data Demonstrating Improved Clinical Outcomes in Patients with Alagille Syndrome Treated with Mirum’s LIVMARLI
BU
Mirum Pharmaceuticals, Inc. Provides Sales Guidance for the Year 2024
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MIRM Stock
  4. News Mirum Pharmaceuticals, Inc.